FDA Approves Selpercatinib for RET+ Lung and Thyroid Cancers
The FDA has approved selpercatinib (formerly known as LOXO-292; Retevmo™) capsules for the treatment of patients with lung cancer or thyroid cancer harboringRETalterations.This marks the first treatment approved to targetRETgene alterations.
Return